A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effects of Sotagliflozin on Clinical Outcomes in Hemodynamically Stable Patients with Type 2 Diabetes POST Worsening Heart Failure
Phase of Trial: Phase III
Latest Information Update: 05 Dec 2019
Price : $35 *
At a glance
- Drugs Sotagliflozin (Primary)
- Indications Cardiovascular disorders; Heart failure
- Focus Registrational; Therapeutic Use
- Acronyms SOLOIST-WHF
- Sponsors Sanofi
- 14 Jun 2018 Status changed from not yet recruiting to recruiting.
- 15 May 2018 Planned initiation date changed from 14 May 2018 to 14 Jun 2018.
- 09 May 2018 New trial record